IRIS Accounts Production v25.4.12.37 07440888 Board of Directors 30.6.25 1.7.24 30.6.25 30.6.25 Medium entities These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. providing social care with accommodation. 323 285 true true true false true true false false false false false false false false true false Ordinary 0 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 07440888 2024-06-30 07440888 2025-06-30 07440888 2024-07-01 2025-06-30 07440888 2023-06-30 07440888 2023-07-01 2024-06-30 07440888 2024-06-30 07440888 ns15:EnglandWales 2024-07-01 2025-06-30 07440888 ns14:PoundSterling 2024-07-01 2025-06-30 07440888 ns10:Director1 2024-07-01 2025-06-30 07440888 ns10:Consolidated 2025-06-30 07440888 ns10:ConsolidatedGroupCompanyAccounts 2024-07-01 2025-06-30 07440888 ns10:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 07440888 ns10:Consolidated ns10:MediumEntities 2024-07-01 2025-06-30 07440888 ns10:Consolidated ns10:Audited 2024-07-01 2025-06-30 07440888 ns10:Medium-sizedCompaniesRegimeForDirectorsReport 2024-07-01 2025-06-30 07440888 ns10:Medium-sizedCompaniesRegimeForAccounts 2024-07-01 2025-06-30 07440888 ns10:Consolidated 2024-07-01 2025-06-30 07440888 ns10:Consolidated ns10:Medium-sizedCompaniesRegimeForDirectorsReport 2024-07-01 2025-06-30 07440888 ns10:Medium-sizedCompaniesRegimeForAccounts ns10:Consolidated 2024-07-01 2025-06-30 07440888 ns10:FullAccounts 2024-07-01 2025-06-30 07440888 ns5:Subsidiary1 2024-07-01 2025-06-30 07440888 ns5:Subsidiary2 2024-07-01 2025-06-30 07440888 ns5:Subsidiary3 2024-07-01 2025-06-30 07440888 ns5:Subsidiary4 2024-07-01 2025-06-30 07440888 ns5:Subsidiary5 2024-07-01 2025-06-30 07440888 ns5:Subsidiary6 2024-07-01 2025-06-30 07440888 ns10:OrdinaryShareClass1 2024-07-01 2025-06-30 07440888 ns10:Director2 2024-07-01 2025-06-30 07440888 ns10:Director3 2024-07-01 2025-06-30 07440888 ns10:RegisteredOffice 2024-07-01 2025-06-30 07440888 ns10:Consolidated 2023-07-01 2024-06-30 07440888 ns5:CurrentFinancialInstruments 2025-06-30 07440888 ns5:CurrentFinancialInstruments 2024-06-30 07440888 ns5:Non-currentFinancialInstruments 2025-06-30 07440888 ns5:Non-currentFinancialInstruments 2024-06-30 07440888 ns5:ShareCapital 2025-06-30 07440888 ns5:ShareCapital 2024-06-30 07440888 ns5:RetainedEarningsAccumulatedLosses 2025-06-30 07440888 ns5:RetainedEarningsAccumulatedLosses 2024-06-30 07440888 ns5:ShareCapital 2023-06-30 07440888 ns5:RetainedEarningsAccumulatedLosses 2023-06-30 07440888 ns5:RetainedEarningsAccumulatedLosses 2023-07-01 2024-06-30 07440888 ns5:RetainedEarningsAccumulatedLosses 2024-07-01 2025-06-30 07440888 ns5:CostValuation 2024-06-30 07440888 1 ns5:Subsidiary1 2024-07-01 2025-06-30 07440888 ns5:Subsidiary2 3 2024-07-01 2025-06-30 07440888 5 ns5:Subsidiary3 2024-07-01 2025-06-30 07440888 ns5:Subsidiary4 7 2024-07-01 2025-06-30 07440888 9 ns5:Subsidiary5 2024-07-01 2025-06-30 07440888 ns5:Subsidiary6 11 2024-07-01 2025-06-30 07440888 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-06-30 07440888 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-06-30 07440888 ns5:Non-currentFinancialInstruments ns5:BetweenOneTwoYears 2025-06-30 07440888 ns5:Non-currentFinancialInstruments ns5:BetweenOneTwoYears 2024-06-30 07440888 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2025-06-30 07440888 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2024-06-30 07440888 ns5:Secured 2025-06-30 07440888 ns5:Secured 2024-06-30 07440888 ns10:OrdinaryShareClass1 2025-06-30 07440888 ns5:RetainedEarningsAccumulatedLosses 2024-06-30

REGISTERED NUMBER: 07440888 (England and Wales)

Group Strategic Report, Report of the Directors and

Consolidated Financial Statements for the Year Ended 30 June 2025

for

NOUVITA HEALTHCARE LTD

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Contents of the Consolidated Financial Statements

for the year ended 30 June 2025

Page |

Company Information | 1 |

Group Strategic Report | 2 |

Report of the Directors | 4 |

Report of the Independent Auditors | 6 |

Consolidated Statement of Comprehensive Income | 10 |

Consolidated Statement of Financial Position | 11 |

Company Statement of Financial Position | 12 |

Consolidated Statement of Changes in Equity | 13 |

Company Statement of Changes in Equity | 14 |

Consolidated Statement of Cash Flows | 15 |

Notes to the Consolidated Statement of Cash Flows | 16 |

Notes to the Consolidated Financial Statements | 17 |

NOUVITA HEALTHCARE LTD

Company Information

for the year ended 30 June 2025

| DIRECTORS: | L V Adams

| P C Massetti

| H Anstey

| REGISTERED OFFICE: | Broad Oak Manor

| Broad Oak End

| Bramfield Road

| Hertford

| Hertfordshire

| SG14 2JA

| REGISTERED NUMBER: | 07440888 (England and Wales)

| AUDITORS: | Thorne Lancaster Parker

| Chartered Accountants &

| Statutory Auditors

| 5th Floor

| Palladium House

| 1-4 Argyll Street

| London

| W1F 7TA

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Group Strategic Report

for the year ended 30 June 2025

The directors present their strategic report of the company and the group for the year ended 30 June 2025.

The primary activity of the Group in the year under review was that of providing in-patient and residential mental healthcare services including; psychiatric intensive care, rehabilitation and long term mental health residential care with and without nursing, primarily to the NHS. Nouvita Healthcare also developed additional services which included supported living and care for young adults with Autism and Learning Disabilities.

The Group's strategy is one of continued growth through the expansion of existing facilities and also through the appropriate acquisition of additional units of suitable quality and location within the southeast of England.

REVIEW OF BUSINESS

| 2025 |  | 2024 |  | 2023 |  |

Turnover |  | £19,596,222 |  | £17,479,321 |  | £16,647,851 |  |

EBITDA |  | £3,276,167 |  | £3,237,604 |  | £3,010,734 |  |

The Board acknowledges a good performance in terms of overall revenue but EBITDA has come under pressure.

Group turnover for the year of £19,596,222 was up approximately 12% from the prior year. The Group EBITDA was £3,276,167 resulting in a Group Profit Before Tax and Impairment of £2,234,618 (2024 £2,152,003).

The Directors see the biggest challenges going forward are related to increasing staff costs and fee rates remaining under pressure. Whilst the Group enjoyed a 12% increase in turnover this was counterbalanced by just over an 18% increase is wages and employment costs. What we are seeing is a staffing cost pressure that all companies have to endure or work around. Nouvita will be exploring how those cost increases can be managed without any effect on the quality of care.

We continue to search for talent that can enhance and build upon our data and training departments to improve overall efficiency and effectiveness.

Working relationships and brand reputation with our commissioners and care co-ordination teams both within the NHS and Local Authorities remain good and having built on those relationships we are looking to build upon bed numbers. This includes expansion plans with existing properties and the acquisition of additional units including new operations in Bedfordshire and Surrey. We increased bed numbers by c 15% in the year and continue to search for more sites in adjacent counties.

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Group Strategic Report

for the year ended 30 June 2025

PRINCIPAL RISKS AND UNCERTAINTIES

The directors analyse key risks to the business and monitor exposure to these risks on a regular basis.

Reputation risk

Provision of poor or inappropriate levels of care would cause severe damage to our CQC ratings, the Group's reputation, and the ability of the business to attract new residents. The business now operates sophisticated levels of performance monitoring systems with regular reporting to senior management and the directors of any potential issues. In addition, a comprehensive programme of service audits is undertaken across the homes with reports and resulting action plans being the subject of regular review. The directors encourage a culture of reporting any concerns from staff, residents and relatives all of which are appropriately investigated.

Health & Safety

The directors are of the view that no serious injury to staff, residents, their guests, or anyone else on the Group's premises is acceptable. Everyone in the business has accountability for health and safety, and they are given the necessary tools (including training, safety equipment and resources) to operate safely. Compliance is organised and monitored through a dedicated health and safety team across the business.

Employment of staff

The Group relies on the skills and expertise of the staff employed. As the economy recovers, the shortage of appropriate labour is a potential risk to the business. This is particularly felt with the national shortage of qualified nursing staff. In order to mitigate this risk, the business has a proactive Human Resources and Recruitment team, including recruitment from overseas. The business continues to invest in a wide range of training courses both internally and externally. Management recognises that in order to deliver a high level of care, our people have to be trained to a very high standard of ability.

FUTURE DEVELOPMENT

The Directors are pleased with the performance of the Group since the year end as the Group's trading performance has improved as the Group continues to seek revenue growth.

ON BEHALF OF THE BOARD:

P C Massetti - Director

11 February 2026

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Report of the Directors

for the year ended 30 June 2025

The directors present their report with the financial statements of the company and the group for the year ended 30 June 2025.

DIVIDENDS

During the year the Group paid a dividend of £1,000,000 (2024:£879,714).

EVENTS SINCE THE END OF THE YEAR

Information relating to events since the end of the year is given in the notes to the financial statements.

DIRECTORS

The directors shown below have held office during the whole of the period from 1 July 2024 to the date of this report.

L V Adams

P C Massetti

H Anstey

GOING CONCERN

The directors have reviewed the 12-month period cashflows to 30th June 2028. Based on the results of the review the directors believe the company has sufficient resources to continue as a going concern for the foreseeable future and as such consider the going concern basis for the preparation of the financial statements to be appropriate.

FINANCIAL INSTRUMENTS

The company's principal financial instruments consist of bank loans, cash and cash equivalents, trade creditors and trade debtors. The main purpose of these instruments is to finance the company's operations.

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

- | select suitable accounting policies and then apply them consistently;

- | make judgements and accounting estimates that are reasonable and prudent;

- | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the group's auditors are aware of that information.

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Report of the Directors

for the year ended 30 June 2025

AUDITORS

The auditors, Thorne Lancaster Parker, are deemed to be re-appointed under Section 487(a) of the Companies Act 2006.

ON BEHALF OF THE BOARD:

P C Massetti - Director

11 February 2026

Report of the Independent Auditors to the Members of

Nouvita Healthcare Ltd

Opinion

We have audited the financial statements of Nouvita Healthcare Ltd (the 'parent company') and its subsidiaries (the 'group') for the year ended 30 June 2025 which comprise the Consolidated Statement of Comprehensive Income, Consolidated Statement of Financial Position, Company Statement of Financial Position, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Statement of Cash Flows and Notes to the Consolidated Statement of Cash Flows, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- | give a true and fair view of the state of the group's and of the parent company affairs as at 30 June 2025 and of the group's profit for the year then ended;

- | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- | have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- | the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and

- | the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of

Nouvita Healthcare Ltd

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- | adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or

- | the parent company financial statements are not in agreement with the accounting records and returns; or

- | certain disclosures of directors' remuneration specified by law are not made; or

- | we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page four, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of

Nouvita Healthcare Ltd

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory frameworks that are applicable to the Group and determined that the most significant are those that relate to the reporting framework (FRS 102 and the Companies Act 2006) and compliance with the relevant direct and indirect tax regulation in the United Kingdom. In addition, the Group has to comply with laws and regulations relating to its operations, including UK employment laws, health and safety, and GDPR.

- We understood how Nouvita Healthcare Limited is complying with those frameworks by making enquires with management and those charged with governance to understand how the Group maintains and communicates policies and procedures in these areas. We understood any controls put in place by management to reduce the opportunities of fraudulent transactions.

- We assessed the susceptibility of the Group's financial statements to material misstatements including how fraud might occur through internal team conversations and inquiry of management and those charged with governance. Through these procedures we determined there to be a risk of management override associated with revenue and a fraud risk around transactions at the year end. We have performed tests of detail, including understanding of the nature of the transactions, verifying that the margin is appropriate, and verifying the clerical accuracy of the revenue recognised. In relation to management override, we selected a sample from the entire population of journals, including manual journals, identifying specific transactions which did not meet our expectations, in order to investigate, understand and agree to source documentation. We selected a sample of revenue transactions recorded before the year end and obtained documentation to verify that revenue adjustments had been recorded in the appropriate period.

- Based on this understanding we designed our audit procedures to identify non-compliance with such laws and regulations. Our procedures involved verifying that material transactions are recorded in compliance with FRS 102 and where appropriate Companies Act 2006. Compliance with other operational laws and regulations were covered through our inquiry with no indication of non-compliance identified.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of

Nouvita Healthcare Ltd

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Neil Usher BA(Hons) FCA (Senior Statutory Auditor)

for and on behalf of Thorne Lancaster Parker

Chartered Accountants &

Statutory Auditors

5th Floor

Palladium House

1-4 Argyll Street

London

W1F 7TA

11 February 2026

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Consolidated Statement of Comprehensive Income

for the year ended 30 June 2025

| 2025 |  | 2024

| Notes | £ | £ |

REVENUE | 19,596,522 |  | 17,479,321 |  |

Cost of sales | (15,034,340 | ) | (12,966,279 | ) |

GROSS PROFIT | 4,562,182 |  | 4,513,042 |  |

Administrative expenses | (1,759,847 | ) | (1,702,443 | ) |

OPERATING PROFIT | 5 | 2,802,335 |  | 2,810,599 |  |

Interest receivable and similar income | 63,070 |  | 43,699 |  |

2,865,405 |  | 2,854,298 |  |

Impairment of property | 6 | - |  | (729,806 | ) |

2,865,405 |  | 2,124,492 |  |

Interest payable and similar expenses | 7 | (630,786 | ) | (702,295 | ) |

PROFIT BEFORE TAXATION | 2,234,619 |  | 1,422,197 |  |

Tax on profit | 8 | (570,988 | ) | (566,081 | ) |

PROFIT FOR THE FINANCIAL YEAR | 1,663,631 |  | 856,116 |  |

OTHER COMPREHENSIVE |

Income tax relating to other comprehensive | - |  | - |  |

OTHER COMPREHENSIVE FOR THE YEAR, NET OF INCOME TAX | - |  | - |  |

TOTAL COMPREHENSIVE INCOME FOR THE YEAR | 1,663,631 |  | 856,116 |  |

Profit attributable to:

Owners of the parent | 1,663,631 |  | 856,116 |  |

Total comprehensive income attributable to:

Owners of the parent | 1,663,631 |  | 856,116 |  |

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Consolidated Statement of Financial Position

30 June 2025

| 2025 |  | 2024

| Notes | £ | £ |

FIXED ASSETS

Property, plant and equipment | 11 | 11,595,432 |  | 11,814,103 |  |

Investments | 12 | - |  | - |  |

11,595,432 |  | 11,814,103 |  |

CURRENT ASSETS

Debtors: amounts falling due within one year | 13 | 1,891,982 |  | 1,655,294 |  |

Debtors: amounts falling due after more than one year | 13 | 25,438 |  | 34,688 |  |

Cash at bank and in hand | 3,817,108 |  | 3,759,786 |  |

5,734,528 |  | 5,449,768 |  |

CREDITORS

Amounts falling due within one year | 14 | (1,791,914 | ) | (1,940,537 | ) |

NET CURRENT ASSETS | 3,942,614 |  | 3,509,231 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 15,538,046 |  | 15,323,334 |  |

CREDITORS

Amounts falling due after more than one year | 15 | (8,303,777 | ) | (8,730,696 | ) |

PROVISIONS FOR LIABILITIES | 19 | (579,700 | ) | (601,700 | ) |

NET ASSETS | 6,654,569 |  | 5,990,938 |  |

CAPITAL AND RESERVES

Called up share capital | 20 | 32,545 |  | 32,545 |  |

Retained earnings | 21 | 6,622,024 |  | 5,958,393 |  |

SHAREHOLDERS' FUNDS | 6,654,569 |  | 5,990,938 |  |

The financial statements were approved by the Board of Directors and authorised for issue on 11 February 2026 and were signed on its behalf by:

P C Massetti - Director

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Company Statement of Financial Position

30 June 2025

| 2025 |  | 2024

| Notes | £ | £ |

FIXED ASSETS

Property, plant and equipment | 11 | - |  | - |  |

Investments | 12 | 32,446 |  | 32,446 |  |

32,446 |  | 32,446 |  |

CURRENT ASSETS

Debtors: amounts falling due within one year | 13 | 2,091,274 |  | 2,011,311 |  |

Debtors: amounts falling due after more than one year | 13 | 4,938,383 |  | 5,462,078 |  |

Cash at bank | 2,026,152 |  | 2,014,672 |  |

9,055,809 |  | 9,488,061 |  |

CREDITORS

Amounts falling due within one year | 14 | (592,659 | ) | (592,601 | ) |

NET CURRENT ASSETS | 8,463,150 |  | 8,895,460 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 8,495,596 |  | 8,927,906 |  |

CREDITORS

Amounts falling due after more than one year | 15 | (8,303,777 | ) | (8,730,696 | ) |

NET ASSETS | 191,819 |  | 197,210 |  |

CAPITAL AND RESERVES

Called up share capital | 20 | 32,545 |  | 32,545 |  |

Retained earnings | 21 | 159,274 |  | 164,665 |  |

SHAREHOLDERS' FUNDS | 191,819 |  | 197,210 |  |

Company's profit for the financial year | 994,609 |  | 809,568 |  |

The financial statements were approved by the Board of Directors and authorised for issue on 11 February 2026 and were signed on its behalf by:

P C Massetti - Director

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Consolidated Statement of Changes in Equity

for the year ended 30 June 2025

| Called up |

| share |  | Retained |  | Total

| capital |  | earnings |  | equity

£ | £ | £ |

Balance at 1 July 2023 | 32,545 |  | 5,981,991 |  | 6,014,536 |  |

Changes in equity

Dividends | - |  | (879,714 | ) | (879,714 | ) |

Total comprehensive income | - |  | 856,116 |  | 856,116 |  |

Balance at 30 June 2024 | 32,545 |  | 5,958,393 |  | 5,990,938 |  |

Changes in equity

Dividends | - |  | (1,000,000 | ) | (1,000,000 | ) |

Total comprehensive income | - |  | 1,663,631 |  | 1,663,631 |  |

Balance at 30 June 2025 | 32,545 |  | 6,622,024 |  | 6,654,569 |  |

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Company Statement of Changes in Equity

for the year ended 30 June 2025

| Called up |

| share |  | Retained |  | Total

| capital |  | earnings |  | equity

£ | £ | £ |

Balance at 1 July 2023 | 32,545 |  | 234,811 |  | 267,356 |  |

Changes in equity

Dividends | - |  | (879,714 | ) | (879,714 | ) |

Total comprehensive income | - |  | 809,568 |  | 809,568 |  |

Balance at 30 June 2024 | 32,545 |  | 164,665 |  | 197,210 |  |

Changes in equity

Dividends | - |  | (1,000,000 | ) | (1,000,000 | ) |

Total comprehensive income | - |  | 994,609 |  | 994,609 |  |

Balance at 30 June 2025 | 32,545 |  | 159,274 |  | 191,819 |  |

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Consolidated Statement of Cash Flows

for the year ended 30 June 2025

| 2025 |  | 2024

| Notes | £ | £ |

Cash flows from operating activities

Cash generated from operations | 1 | 3,062,570 |  | 3,465,059 |  |

Interest paid | (630,786 | ) | (702,295 | ) |

Tax paid | (746,375 | ) | (550,671 | ) |

Net cash from operating activities | 1,685,409 |  | 2,212,093 |  |

Cash flows from investing activities

Purchase of tangible fixed assets | (257,115 | ) | (1,055,327 | ) |

Sale of tangible fixed assets | 4,230 |  | - |  |

Interest received | 63,070 |  | 43,699 |  |

Net cash from investing activities | (189,815 | ) | (1,011,628 | ) |

Cash flows from financing activities

Loan repayments in year | (426,919 | ) | (199,542 | ) |

Capital repayments in year | (11,353 | ) | - |  |

Share issue | - |  | 100 |  |

Equity dividends paid | (1,000,000 | ) | (879,714 | ) |

Net cash from financing activities | (1,438,272 | ) | (1,079,156 | ) |

Increase in cash and cash equivalents | 57,322 |  | 121,309 |  |

Cash and cash equivalents at beginning of year | 2 | 3,759,786 |  | 3,638,477 |  |

Cash and cash equivalents at end of year | 2 | 3,817,108 |  | 3,759,786 |  |

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Statement of Cash Flows

for the year ended 30 June 2025

1. | RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

| 2025 |  | 2024

£ | £ |

| Profit before taxation | 2,234,619 |  | 1,422,197 |  |

| Depreciation charges | 473,833 |  | 427,004 |  |

| Profit on disposal of fixed assets | (2,277 | ) | - |  |

| General provision | - |  | 42,200 |  |

| Impairment of property | - |  | 729,806 |  |

| Finance costs | 630,786 |  | 702,295 |  |

| Finance income | (63,070 | ) | (43,699 | ) |

3,273,891 |  | 3,279,803 |  |

| Increase in trade and other debtors | (227,438 | ) | (16,353 | ) |

| Increase in trade and other creditors | 16,117 |  | 201,609 |  |

| Cash generated from operations | 3,062,570 |  | 3,465,059 |  |

2. | CASH AND CASH EQUIVALENTS

| The amounts disclosed on the Statement of Cash Flows in respect of cash and cash equivalents are in respect of these Statement of Financial Position amounts:

| Year ended 30 June 2025

| 30.6.25 |  | 1.7.24

£ | £ |

| Cash and cash equivalents | 3,817,108 |  | 3,759,786 |  |

| Year ended 30 June 2024

| 30.6.24 |  | 1.7.23

£ | £ |

| Cash and cash equivalents | 3,759,786 |  | 3,638,477 |  |

3. | ANALYSIS OF CHANGES IN NET DEBT

| At 1.7.24 | Cash flow | At 30.6.25

£ | £ | £ |

| Net cash |

| Cash at bank and in hand | 3,759,786 |  | 57,322 |  | 3,817,108 |  |

3,759,786 |  | 57,322 |  | 3,817,108 |  |

| Debt

| Finance leases | (11,353 | ) | 11,353 |  | - |  |

| Debts falling due within 1 year | (276,000 | ) | - |  | (276,000 | ) |

| Debts falling due after 1 year | (8,730,696 | ) | 426,919 |  | (8,303,777 | ) |

(9,018,049 | ) | 438,272 |  | (8,579,777 | ) |

| Total | (5,258,263 | ) | 495,594 |  | (4,762,669 | ) |

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements

for the year ended 30 June 2025

1. | STATUTORY INFORMATION

| Nouvita Healthcare Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the General Information page.

2. | STATEMENT OF COMPLIANCE

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

3. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| The company has applied the merger accounting principles in accordance with FRS 102 in the preparation of the consolidated accounts. Under merger accounting, the carrying values of the assets and liabilities of the acquired entities are not adjusted to fair value, although appropriate adjustments are made to achieve uniformity of accounting policies where necessary.

| The results and cashflows of all the combining entities are brought into the consolidated financial statements from the beginning of the financial year in which the combination occurred. In addition the comparative information is restated by including the results for all the combining entities for the previous reporting period and their balance sheet for the previous reporting date as if the entities had been combined throughout the prior period, adjusted as necessary to achieve uniformity of accounting policies.

| These financial statements have been prepared on a going concern basis, under the historical cost convention.

| The Company has taken advantage of the exemption in section 408 of the Companies Act from disclosing its individual profit and loss account.

| Basis of consolidation

| The consolidated accounts as at 30 June 2025 incorporate those of Nouvita Healthcare Limited and all of its subsidiaries.

| The financial period of each subsidiary is co-terminus with that of the parent undertaking.

| A subsidiary is an entity controlled by the Group, by virtue of holding a majority of the equity or an agreement with other investors. Control is the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities.

| Where a subsidiary has different accounting policies to the group, adjustments are made to those subsidiary financial statements to apply the Group's accounting policies when preparing the consolidated financial statements.

| All intra-group transactions, balances, and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

| One subsidiary undertaking of the Company has taken advantage of the audit exemption under section 479A of the Companies Act 2006 for the year ended 30 June 2025.

| The subsidiary concerned is:

| Noucare Partners Limited (registered number 12213485).

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

3. | ACCOUNTING POLICIES - continued

| Significant judgements and estimates

| Estimates and judgements are continually evaluated and are based on historical experience and other factors, including explanations of future events that are believe to be reasonable under the circumstances.

| Key accounting estimates and assumptions

| The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below;

| Useful economic life of property plant and equipment

| The annual depreciation charge for property, plant and equipment is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are assessed annually. They are amended when necessary to reflect current estimates based on technological advancement, future investments, economic utilisation and the physical condition of the assets.

| Going concern

| The directors have reviewed the 12-month period cashflows to 30th June 2028. Based on the results of the review the directors believe the company has sufficient resources to continue as a going concern for the foreseeable future and as such consider the going concern basis for the preparation of the financial statements to be appropriate.

| Turnover

| Turnover

| Revenue is recognised at the fair value of the consideration received or receivable for provision of services to external customers in the ordinary nature of the business. The fair value of the consideration takes into account discounts, settlement discounts and other rebates.

| The Group recognises revenue when the amount of revenue can be measured reliably, and it is probable that future economic benefit will flow to the company.

| Other income

| Other income is recognised on an accruals basis and is presented within other operating income.

| Tangible fixed assets

| Property, plant and equipment are stated at cost (or deemed cost) less accumulated depreciation and accumulated impairment losses. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration initially recorded at cost.

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Freehold Buildings |  | 50 years |  |

| Short leasehold |  | 2 years |  |

| Plant and machinery |  | 4 years |  |

| Motor vehicles |  | 4 years |  |

| No depreciation is charged on Freehold Land.

| The carrying values of property plant and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying value may not be recoverable.

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

3. | ACCOUNTING POLICIES - continued

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Statement of Comprehensive Income, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Hire purchase and leasing commitments

| Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

| The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

| Pension costs and other post-retirement benefits

| The Group operates a defined contribution pension scheme where the amounts charged to profit or loss are the contributions payable in the year. Differences between contributions payable in the year and the contributions actually paid are shown as either accruals or prepayments.

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

3. | ACCOUNTING POLICIES - continued

| Financial instruments

| The Group has chosen to adopt Section 11 of FRS 102 in respect of financial instruments as it has only basic financial instruments.

| Basic financial assets

| Trade and other debtors, loans to fellow group companies, loans to related companies, other debtors and bank balances, which are due within one year are initially recognised at transaction price and subsequently carried at amortised cost being the transaction price less any amounts settled and any impairment losses.

| At the end of each reporting period basic financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in profit or loss.

| If there is decrease in the impairment loss arising from an event occurring after the impairment was recognised the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

| A financial asset is derecognised only when the contractual rights to cash flows expire or are settled, or substantially all the risks and rewards of ownership are transferred to another party, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

| Basic financial liabilities

| Financial liabilities are classified as liabilities and equity instruments according to the substance of the contractual arrangements entered into an equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

| Trade creditors, other creditors and loans from related companies are initially recognised at transaction price and subsequently carried at amortised cost, being transaction price less any amounts settled.

| Bank overdrafts and invoice discounting facility are presented within creditors: amounts falling due within one year.

| Other loans are initially recognised at the transaction price, including transaction costs and subsequently measured at amortised cost using the effective interest method. Interest expense is recognised on the basis of the effective interest method and is included in interest payable and other similar charges.

| Directors loan that are repayable on demand are shown as due within one year and are measured at their nominal value.

| Basic financial liabilities are derecognised when the contractual obligation is discharged, cancelled or expired.

| Equity instruments

| The ordinary share capital of the Group is classified as equity and recorded at fair value of the cash or other resources received or receivable, net of direct costs of issuing the equity instruments.

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

3. | ACCOUNTING POLICIES - continued

| Provisions for liabilities

| Provisions are recognised when the group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation, and the amount of the obligation can be estimated reliably.

| Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations might be small.

| Cash and cash equivalents

| Cash and cash equivalents in the balance sheet comprise of cash at bank and short term deposits.

4. | EMPLOYEES AND DIRECTORS

|  | 2025 |  | 2024 |  |

|  | £ |  | £ |  |

| Wages and Salaries |  | 9,786,045 |  | 7,887,538 |  |

| Social security costs |  | 1,059,729 |  | 774,365 |  |

| Other pension costs |  | 231,548 |  | 197,437 |  |

|  | 11,077,322 |  | 8,859,340 |  |

| The average number of employees during the year was as follows:

|  | 2025 |  | 2024 |  |

| Nurses, carers and administration |  | 323 |  | 285 |  |

|  | 2025 |  | 2024 |  |

|  | £ |  | £ |  |

| Director's remuneration |  | 77,676 |  | 92,182 |  |

5. | OPERATING PROFIT

| The operating profit is stated after charging/(crediting):

| 2025 |  | 2024

£ | £ |

| Hire of plant and machinery | 299 |  | 171 |  |

| Depreciation - owned assets | 473,833 |  | 415,954 |  |

| Depreciation - assets on hire purchase contracts | - |  | 11,050 |  |

| Profit on disposal of fixed assets | (2,277 | ) | - |  |

| Auditors' remuneration | 55,201 |  | 46,500 |  |

| Taxation compliance services | 9,780 |  | 6,400 |  |

6. | IMPAIRMENT OF PROPERTY

| 2025 |  | 2024

£ | £ |

| Impairment of property | - |  | 729,806 |  |

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

7. | INTEREST PAYABLE AND SIMILAR EXPENSES |

| 2025 |  | 2024

£ | £ |

| Bank loan interest | 621,382 |  | 691,816 |  |

| Other interest payable | 154 |  | 1,229 |  |

| Other interest | 9,250 |  | 9,250 |  |

630,786 |  | 702,295 |  |

8. | TAXATION

| Analysis of the tax charge

| The tax charge on the profit for the year was as follows:

| 2025 |  | 2024

£ | £ |

| Current tax:

| UK corporation tax | 592,801 |  | 470,081 |  |

| Over provision of tax | 187 |  | - |  |

| Total current tax | 592,988 |  | 470,081 |  |

| Deferred tax | (22,000 | ) | 96,000 |  |

| Tax on profit | 570,988 |  | 566,081 |  |

| Reconciliation of total tax charge included in profit and loss

| The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

| 2025 |  | 2024

£ | £ |

| Profit before tax | 2,234,619 |  | 1,422,197 |  |

| Profit multiplied by the standard rate of corporation tax in the UK of 25 % (2024 - 25 %) | 558,655 |  | 355,549 |  |

| Effects of:

| Expenses not deductible for tax purposes | 495 |  | 193,152 |  |

| Income not taxable for tax purposes | (569 | ) | - |  |

| Capital allowances in excess of depreciation | - |  | (77,517 | ) |

| Depreciation in excess of capital allowances | 34,220 |  | - |  |

| Adjustments to tax charge in respect of previous periods | 187 |  | - |  |

| Deferred Tax in respect of accelerated capital allowances | (22,000 | ) | 96,000 |  |

| Marginal relief | - |  | (1,103 | ) |

| Total tax charge | 570,988 |  | 566,081 |  |

| Tax effects relating to effects of other comprehensive income |

| There were no tax effects for the year ended 30 June 2025.

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

8. | TAXATION - continued

| 2024 |

| Gross |  | Tax |  | Net |

£ | £ | £ |

9. | INDIVIDUAL STATEMENT OF COMPREHENSIVE INCOME

| As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements.

10. | DIVIDENDS

| 2025 |  | 2024

£ | £ |

| Ordinary shares of 1 each

| Final | 1,000,000 |  | 879,714 |  |

11. | PROPERTY, PLANT AND EQUIPMENT

| Group

| Land and |  | Short |  | Plant and |  | Motor |

| buildings |  | leasehold |  | machinery |  | vehicles |  | Totals

£ | £ | £ | £ | £ |

| COST

| At 1 July 2024 | 12,574,914 |  | 44,712 |  | 3,946,178 |  | 165,929 |  | 16,731,733 |  |

| Additions | - |  | - |  | 231,290 |  | 25,825 |  | 257,115 |  |

| Disposals | - |  | - |  | - |  | (6,250 | ) | (6,250 | ) |

| At 30 June 2025 | 12,574,914 |  | 44,712 |  | 4,177,468 |  | 185,504 |  | 16,982,598 |  |

| DEPRECIATION

| At 1 July 2024 | 1,570,642 |  | 44,712 |  | 3,178,190 |  | 124,086 |  | 4,917,630 |  |

| Charge for year | 114,634 |  | - |  | 335,289 |  | 23,910 |  | 473,833 |  |

| Eliminated on disposal | - |  | - |  | - |  | (4,297 | ) | (4,297 | ) |

| At 30 June 2025 | 1,685,276 |  | 44,712 |  | 3,513,479 |  | 143,699 |  | 5,387,166 |  |

| NET BOOK VALUE

| At 30 June 2025 | 10,889,638 |  | - |  | 663,989 |  | 41,805 |  | 11,595,432 |  |

| At 30 June 2024 | 11,004,272 |  | - |  | 767,988 |  | 41,843 |  | 11,814,103 |  |

| The Group's loan facility is secured against the Group's land and buildings.

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

11. | PROPERTY, PLANT AND EQUIPMENT - continued

| Group

| Fixed assets, included in the above, which are held under hire purchase contracts are as follows:

| Motor

| vehicles

£ |

| COST

| At 1 July 2024 | 70,915 |  |

| Reclassification/transfer | (70,915 | ) |

| At 30 June 2025 | - |  |

| DEPRECIATION

| At 1 July 2024 | 49,614 |  |

| Reclassification/transfer | (49,614 | ) |

| At 30 June 2025 | - |  |

| NET BOOK VALUE

| At 30 June 2025 | - |  |

| At 30 June 2024 | 21,301 |  |

12. | FIXED ASSET INVESTMENTS

| Company

| Shares in

| group

| undertakings

£ |

| COST

| At 1 July 2024

| and 30 June 2025 | 32,446 |  |

| NET BOOK VALUE

| At 30 June 2025 | 32,446 |  |

| At 30 June 2024 | 32,446 |  |

| The group or the company's investments at the Statement of Financial Position date in the share capital of companies include the following:

| Subsidiaries

| Nouvita Limited

| Registered office: Broad oak Manor, Broad Oak End, Bramfield Road, Hertford, Hertfordshire, SG14 2JA

| Nature of business: Providing social care with accommodation

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

12. | FIXED ASSET INVESTMENTS - continued

| Psycare Limited

| Registered office: Broad oak Manor, Broad Oak End, Bramfield Road, Hertford, Hertfordshire, SG14 2JA

| Nature of business: Operation and management of psychiatric care homes

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

| Yovita Limited

| Registered office: Broad oak Manor, Broad Oak End, Bramfield Road, Hertford, Hertfordshire, SG14 2JA

| Nature of business: Building a care home

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

| Noucare Partners Limited

| Registered office: Broad oak Manor, Broad Oak End, Bramfield Road, Hertford, Hertfordshire, SG14 2JA

| Nature of business: Procurement and provision of agency services

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

| Baldock Care Limited

| Registered office: Broad oak Manor, Broad Oak End, Bramfield Road, Hertford, Hertfordshire, SG14 2JA

| Nature of business: Dormant

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

| Yovita Healthcare Limited

| Registered office: Broad oak Manor, Broad Oak End, Bramfield Road, Hertford, Hertfordshire, SG14 2JA

| Nature of business: Dormant

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

| On 1 July 2019 under a group share restructure, the company acquired the entire share capital of the entities listed above.

13. | DEBTORS

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Amounts falling due within one year: |

| Trade debtors | 1,777,964 |  | 1,484,868 |  | - |  | - |  |

| Amounts owed by group undertakings | - |  | - |  | 2,091,174 |  | 2,009,585 |  |

| Other debtors | 23,848 |  | 67,441 |  | 100 |  | 100 |  |

| Prepayments and accrued income | 90,170 |  | 102,985 |  | - |  | 1,626 |  |

1,891,982 |  | 1,655,294 |  | 2,091,274 |  | 2,011,311 |  |

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

13. | DEBTORS - continued

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Amounts falling due after more than one | year: |

| Amounts owed by group undertakings | - |  | - |  | 4,912,945 |  | 5,427,390 |  |

| Prepayments and accrued income | 25,438 |  | 34,688 |  | 25,438 |  | 34,688 |  |

25,438 |  | 34,688 |  | 4,938,383 |  | 5,462,078 |  |

| Aggregate amounts | 1,917,420 |  | 1,689,982 |  | 7,029,657 |  | 7,473,389 |  |

| Trade debtors are stated after provisions for bad debts of £1,044 (2024: £145,751).

| Of the amounts owed by group undertakings due within one year, £503,030 are unsecured, have no fixed date for repayment and are interest free and £4,409,915 are unsecured, due for repayment in within one year and interest of 2.6% over the base rate is being charged.

| Amounts owed by group undertakings due after more than one year are unsecured, due for repayment by 30 June 2027 and interest of 2.6% over the base rate is being charged.

14. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Bank loans and overdrafts (see note 16) | 276,000 |  | 276,000 |  | 276,000 |  | 276,000 |  |

| Hire purchase contracts (see note 17) | - |  | 11,353 |  | - |  | - |  |

| Trade creditors | 720,557 |  | 644,643 |  | - |  | - |  |

| Amounts owed to group undertakings | - |  | - |  | 300,000 |  | 300,000 |  |

| Tax | 319,727 |  | 473,114 |  | - |  | - |  |

| Social security and other taxes | 272,477 |  | 263,125 |  | - |  | - |  |

| Other creditors | 122,220 |  | 104,543 |  | - |  | - |  |

| Accruals and deferred income | 80,933 |  | 167,759 |  | 16,659 |  | 16,601 |  |

1,791,914 |  | 1,940,537 |  | 592,659 |  | 592,601 |  |

| Amounts owed to related undertakings are unsecured, interest free, have no fixed date of repayment and are repayable on demand.

15. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Bank loans (see note 16) | 8,303,777 |  | 8,730,696 |  | 8,303,777 |  | 8,730,696 |  |

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

16. | LOANS

| An analysis of the maturity of loans is given below:

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Amounts falling due within one year or on | demand: |

| Bank loans | 276,000 |  | 276,000 |  | 276,000 |  | 276,000 |  |

| Amounts falling due between one and two | years: |

| Bank loans - 1-2 years | 276,000 |  | 276,000 |  | 276,000 |  | 276,000 |  |

| Amounts falling due between two and five | years: |

| Bank loans - 2-5 years | 8,027,777 |  | 8,454,696 |  | 8,027,777 |  | 8,454,696 |  |

17. | LEASING AGREEMENTS

| Minimum lease payments fall due as follows:

| Group

| Hire purchase |

| contracts |

2025 | 2024 |

£ | £ |

| Net obligations repayable:

| Within one year | - |  | 11,353 |  |

| Group

| Non-cancellable |

| operating leases |

2025 | 2024 |

£ | £ |

| Within one year | - |  | 46,076 |  |

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

18. | SECURED DEBTS

| The following secured debts are included within creditors:

| Group |  | Company |

2025 | 2024 | 2025 | 2024 |

£ | £ | £ | £ |

| Bank loans | 8,579,777 |  | 9,006,696 |  | 8,579,777 |  | 9,006,696 |  |

| Hire purchase contracts | - |  | 11,353 |  | - |  | - |  |

8,579,777 |  | 9,018,049 |  | 8,579,777 |  | 9,006,696 |  |

| In March 2023 the Group entered into a new facility of £9.25m which was used in relation to refinancing the previous loan facility and provide additional funding for designated capital expenditure.

| This facility is repayable over a period of 5 years and interest is charged at 2.35% over the Bank of England base rate and is secured by way of a legal charge over the group's properties.

| Hire purchases are secured against the assets they relate to.

19. | PROVISIONS FOR LIABILITIES

| Group |

2025 | 2024 |

£ | £ |

| Deferred tax | 287,500 |  | 309,500 |  |

| Other provisions | 292,200 |  | 292,200 |  |

| Aggregate amounts | 579,700 |  | 601,700 |  |

| Group

| Deferred |  | Other |

| tax |  | provisions |

£ | £ |

| Balance at 1 July 2024 | 309,500 |  | 292,200 |  |

| Credit to Statement of Comprehensive Income during year | (22,000 | ) | - |  |

| Balance at 30 June 2025 | 287,500 |  | 292,200 |  |

| The other provision of £292,200 is in relation to a general provision for costs that the business may incur in relation to its business activities.

20. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 32,545 | Ordinary | 1 | 32,545 |  | 32,545 |  |

NOUVITA HEALTHCARE LTD (REGISTERED NUMBER: 07440888)

Notes to the Consolidated Financial Statements - continued

for the year ended 30 June 2025

21. | RESERVES

| Group

| Retained

| earnings

£ |

| At 1 July 2024 | 5,958,393 |  |

| Profit for the year | 1,663,631 |  |

| Dividends | (1,000,000 | ) |

| At 30 June 2025 | 6,622,024 |  |

| Company

| Retained

| earnings

£ |

| At 1 July 2024 | 164,665 |  |

| Profit for the year | 994,609 |  |

| Dividends | (1,000,000 | ) |

| At 30 June 2025 | 159,274 |  |

22. | CONTINGENT LIABILITIES

| The Group has an unlimited multilateral banking guarantee with fellow group companies. At the balance sheet date the total amount outstanding under the agreement was £8.58m.

23. | POST BALANCE SHEET EVENTS

| No post balance sheet events were identified.

24. | ULTIMATE CONTROLLING PARTY

| The controlling party is L V Adams.